BioPharmSignal logoBioPharmSignal

Biotech News

Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference

Karyopharm Therapeutics (KPTI)Karyopharm TherapeuticsConference / presentation

KPTI (KPTI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is kpti.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

KPTIKaryopharm Therapeutics2026-08-13 11:30 EST

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

KPTIKaryopharm Therapeutics2026-08-03 20:05 EST

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

MMSIMerit Medical2026-08-05 16:00 EST

Merit Medical to Participate in Upcoming Investors Conferences in August

View all latest news

Karyopharm Therapeutics

Nuclear Export Oncology Company Karyopharm Therapeutics is a commercial-stage oncology company built around inhibition of exportin 1, a nuclear export protein involved in cancer-cell survival. XPOVIO Franchise XPOVIO, or selinexor, is commercialized in hematologic malignancies and provides the commercial base for development in...

Recent company news

KPTIKaryopharm Therapeutics2026-08-13 11:30 EST

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

KPTIKaryopharm Therapeutics2026-08-10 11:30 EST

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

KPTIKaryopharm Therapeutics2026-08-03 20:05 EST

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

KPTIKaryopharm Therapeutics2026-07-30 20:06 EST

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

KPTIKaryopharm Therapeutics2026-07-30 20:05 EST

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

Stock data

Close
1.96 USD
Market cap
209.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States